Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Drugs for the Treatment of Multiple Sclerosis and Risk of Cancer: a Pharmacovigilance Analysis in Vigibase

NCT04237337 is registered in ClinicalTrials.gov with University Hospital, Caen as lead sponsor.

NCT NCT04237337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04237337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Drugs for the Treatment of Multiple Sclerosis and Risk of Cancer: a Pharmacovigilance Analysis in Vigibase
Lead sponsor
University Hospital, Caen
Phase
Observational
Overall status
Unknown status
Start date
January 31, 2020
Completion date
March 31, 2020
Enrollment
200,000 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

malignant tumor, multiple sclerosis